Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2024-04-29 Annual Report
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
2023 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is a comprehensive report from Pharmaron Beijing Co., Ltd. covering the business performance results for the year ended December 31, 2023. It includes detailed sections such as Chairman's Statement, Financial Highlights, Management Discussion and Analysis, Profile of Directors, Corporate Governance Report, Independent Auditor's Report, and Consolidated Financial Statements. The presence of full financial statements and extensive narrative on business performance and outlook indicates this is a full annual report. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-04-25 English
ANNOUNCEMENT ON THE PLAN OF REPURCHASE OF A SHARES OF THE COMPANY THROUGH BIDDING
Transaction in Own Shares Classification · 95% confidence The document is an announcement by Pharmaron Beijing Co., Ltd. regarding a plan to repurchase its A shares through bidding on the Shenzhen Stock Exchange. It details the purpose, price, amount, method, period, and expected impact of the share repurchase. The document is regulatory in nature, providing information about a capital action (share repurchase) but does not contain financial statements or earnings data. It is not a full financial report, earnings release, or management discussion. The content fits the category of a company announcement about share repurchase activity, which corresponds to 'Transaction in Own Shares' (POS). The document is lengthy and detailed, not a brief notice or a report publication announcement. Therefore, the appropriate classification is POS with high confidence.
2024-04-25 English
CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT
Board/Management Information Classification · 100% confidence The document is an announcement from Pharmaron Beijing Co., Ltd. regarding the resignation of the company secretary and the appointment of a new company secretary, authorised representative, and process agent. It details changes in senior management roles related to corporate governance but does not contain financial data, earnings, or report content. The document is not a full report, financial statement, or regulatory filing of financial results. It clearly fits the category of Board/Management Information (MANG) as it announces changes in the company's board or senior management positions.
2024-04-25 English
2024 FIRST QUARTERLY REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 FIRST QUARTERLY REPORT' and contains detailed financial data for the first quarter of 2024, including revenue, net profit, earnings per share, cash flows, and segment performance. It references compliance with accounting standards and includes management's discussion of financial results and reasons for changes in financial indicators. The document is about 15,000 characters long, which is substantial and contains actual financial statements and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-04-18 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.